GlassScriptPhysician profile
Srinivas Channapragada
NPI 1801944632
$1,266.36
in general payments reported to CMS, 2019-2025
17 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $58.58 · 2021: $42.03 · 2022: $53.60 · 2023: $142 · 2024: $447 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $777.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $377.32 | 2019-2024 | Mavyret |
| Madrigal Pharmaceuticals | $264.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.01 | 2019-2024 | Plenvu, Trulance, Xifaxan |
| Echosens North America, INC. | $98.13 | 2024 | Fibroscan |
| Qol Medical, LLC | $65.70 | 2023-2024 | Sucraid, Sucraid |
| Novo Nordisk INC | $52.87 | 2023-2024 | |
| Lilly USA, LLC | $31.25 | 2023-2024 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $28.21 | 2025 | Voquezna |
| Genzyme Corporation | $20.38 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.32 | 2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $17.63 | 2024 | Dupixent |
| Celltrion USA INC. | $17.14 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $16.04 | 2024 | |
| Alnylam Pharmaceuticals INC. | $14.97 | 2024 | Givlaari |
| Alexion Pharmaceuticals, INC. | $14.67 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $12.68 | 2022 | |
| Daiichi Sankyo INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivas Channapragada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.